COVID-19 vaccine progress: time to market / pricing / order of vaccination

On the 25th, the State Council Information Office held a briefing to introduce the progress of the new coronavirus vaccine work. Zheng Zhongwei, head of the Vaccine R&D Special Team of the Scientific Research Group and Director of the National Health and Health Commission's Medical Science and Technology Development Center, said that he will go all out and race against the clock to promote my country's new crown virus vaccine as soon as possible.

Regarding the public concern about the price of the new coronavirus vaccine after the launch, Zheng Zhongwei said that it will definitely meet the accessibility and affordability, and propose a guide price within the acceptable range of the public. Zheng Zhongwei said that the public product attribute of the new coronavirus vaccine is basically to follow its pricing. Since it is a public product, it must meet its accessibility and affordability. After the official launch, the new crown pneumonia vaccine will be adjusted in price according to other factors such as technical route and scale of use.

He said that he will be stratified according to the three categories of high-risk groups, high-risk groups, and the general population to satisfy the new crown vaccination. According to current estimates, by the end of this year, the annual production capacity of the new crown vaccine is expected to reach 610 million doses. By next year, the annual production capacity can reach more than 1 billion doses.